Studies
1) Prevent study. Επιπολασμός της ασυμπτωματικής εν τω βάθει φλεβικής θρόμβωσης (DVT) σε ασθενείς με καρκίνο. Δεδομένα που προέρχονται από συνθήκες καθημερινής κλινικής πρακτικής στην Ελλάδα (ΠΓΝΛ)
2) TESARO - BRAVO. A phase III, randomized, open label, multicenter, controlled trial of niraparib versus physician’s choice in previously treated, HER2 negative, germline BRCA mutation-positive breast cancer patients. (Sub-Investigator)
https://clinicaltrials.gov/ct2/show/NCT01905592?term=TESARO+-+BRAVO&rank=1
3) PUMA. A Randomized, Double-Blind, Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women with Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer (Sub-Investigator) https://clinicaltrials.gov/ct2/show/NCT00878709?term=Neratinib+%28HKI- 272%29+After+Trastuzumab&rank=1
4) ELUXA 3. An international, randomised, multi-centre, active-controlled, open-label Phase III study evaluating the efficacy of BI 1482694 versus afatinib as first line treatment in patients with locally advanced or metastatic non-small cell lung cancer carrying epidermal growth factor receptor activating mutations. (Sub-Investigator)
http://adisinsight.springer.com/trials/700273106
5) ELI LILLY (I4T-MC-JVCP RAM EAP). An International Single-Arm Protocol to Provide Expanded Access to Ramucirumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression after prior Fluoropyrimidine and/or Platinoum-Containing Chemotherapy. (Sub- Investigator)
https://clinicaltrials.gov/ct2/show/NCT02065765?term=I4T-MC-JVCP&rank=1
6) FUJIFILM study. A Randomized, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastin® in 1st Line Treatment for Patients with Advanced/Recurrent Non Squamous Non-Small Cell Lung Cancer in Combination of Paclitaxel and Carboplatin. (Sub-Investigator) https://clinicaltrials.gov/ct2/show/NCT02810457?term=FKB238&rank=1
AVANA Investigator Meeting, will be taking place 30 June – 1 July 2016, in Athens, Greece (Sub-Investigator)
7) GO29432 study. A phase III, open-label, randomized study of MPDL3280A (ANTI−PDL1 antibody) compared with Gemcitabine + Cisplatin or Carboplatin for PD-L1−Selected, chemotherapy naïve patients with stage IV Squamous Non-Small Cell Lung Cancer. (Sub-Investigator) https://clinicaltrials.gov/ct2/show/NCT02409355?term=GO29432+study&rank=1
8) 1301 study. Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD)
(Sub-Investigator)
https://clinicaltrials.gov/ct2/show/NCT02485691?term=cabazitaxel&cntry=GR&rank =5
9) AZD9291. Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC
(Sub-Investigator)
https://clinicaltrials.gov/ct2/show/NCT02771314?term=AZD+osimertinib&cntry=GR &rank=1
10) MINOAS study. Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment (MINOAS)
(Sub-Investigator)
https://clinicaltrials.gov/ct2/show/NCT02624726
11) Μη παρεμβατική μελέτη παρατήρησης της κλινικής πρακτικής στην Ελλάδα στην Αντιμετώπιση του Μεταστατικού Καρκίνου του Παγκρέατος – ΕΟΠΕ (Sub- Investigator)
International Congress Participations
- World Congress of Psycho-Oncology and Psychosocial Academy Workshops in Washington. Washington DC, USA, 28 July to 1 August 2015
- ENET Annual Conference in Barcelona. 11-13 March 2015
- Medical Oncology & Hematology Board Review Course. Athens 28-31 January 2015
- 2014 San Antonio Breast Cancer Symposium. San Antonio Texas 9-13 December 2014
- ESMO Symposium on Immuno-Oncology 2014. Geneva Switzerland 21-22 November 2014
- ESMO Preceptorship on Immunotherapy of Cancer. Lausanne Switzerland 19-20 November 2014
- 2nd International Symposium ACTC Advances in Circulating Tumor Cells (ACTC): From Basic Research to Clinical Practice. 8-11 October 2014
- 39th ESMO Congress – ESMO 2014. Madrid, Spain (26-30/09/2014)
- ESMO 16th World Congress on Gastrointestinal Cancer. Barcelona, Spain (25/06/2014)
- International Symposium Advances and Perspectives in Gastrointestinal Oncology. Labelled Meeting ESMO. Delphi, Greece (13/03/2014)
- IASLC Best of World Conference on Lung Cancer. Athens (28/02/2014)
- 3rd Lung Cancer Network "From the Bench to the Bedside". Accreditation from ESMO, Athens (31/01/2014)
- 3rd Congress of the Mediterranean Multidisciplinary Oncology Forum. Under the Auspice of ESMO, Athens (24/10/2013)
- Best of ASCO 2013 - Hellenic Society of Medical Oncology. Eretria, Greece (20/09/ 2013)
- ASCO Annual Meeting 2013. USA, Chicago (31/05/2013)
- Preceptorship – Integrated Management of Cancer Patients. Medical School, University of Crete, Greece (12/11/2012)
- 37th ESMO Congress 2012. Vienna, Austria (28/09/2012)
- Best of ASCO 2012 - Hellenic Society of Medical Oncology. Eretria, Greece (14/09/ 2012)
- 7th World Research Congress of the European Association for Palliative Care. Trondheim, Norway (07/06/2012)
Articles in magazines
1) Immunotherapy of Cancer. Developments and Reference Points, an Unorthodox Approach.
M. Nikolaou, G. Nikolaou, A. Digklia , Ch. Pontas , N. Tsoukalas, G. Kyrgias , M. Tolia
Integrative Cancer Therapies Impact Factor 2.657
2) Bcl-2 expression in circulating tumor cells (CTCs) of patients with small cell lung cancer (SCLC) receiving front-line treatment
I. Messaritakis, M. Nikolaou, E. Politaki, F. Koinis, E. Lagoudaki, A. Koutsopoulos, N. Georgoulia, V. Georgoulias, A. Kotsakis
Lung Cancer Impact Factor 4.486
3) Stage-II Thymoma and emergency coronary artery bypass. To irradiate or not to irradiate to avoid radiation induced vascular injury? Case Report and Literature Review
I. Kouerinis, M. Tolia, F. Zagouri, M. Nikolaou, N. Tsoukalas, G. Kyrgias, M. Dimopoulos, C. Vlachopoulos, I. Karathanassis, M. Zoubouli, I. Kokakis, V. Kouloulias, K. Triantafillou
JBUON - Impact factor 1.766
4) How Can We Effectively Address the Paraneoplastic Dermatomyositis: Diagnosis, Risk Factors and Treatment Options
I. Zerdes, M. Tolia, M. Nikolaou, N. Tsoukalas, L. Velentza, J. Hajiioannou, M. Mitsis, G. Kyrgias.
JBUON I.F 1.344
5) Addressing the post-irradiation hypothalamic-pituitary endocrine abnormalities of brain tumors in pediatric patients
L. Velentza, M. Tolia, C. Christakou, M. Nikolaou, I. Zerdes, N. Tsoukalas, J. Hajiioannou, K. Tsanadis, G. Rigas, M. Mitsis, K. Theodorou, K. Pistevou-Gombaki, P. Tsekeris, G. Kyrgias
JBUON I.F 1.344
6) Percutaneous-computed-tomography- guided localization of pulmonary nodules with hook wire prior to video-assisted thoracoscopic surgery
S. Manouvelou, E. Mosa, M. Tolia, N. Tsoukalas, M. Nikolaou, G. Nikolaou, A. Dountsis, E. Andriotis, K. Vasilikos, G. Kyrgias
JBUON I.F 1.344
7) Clinical value of significance of Hypoxia Inducible Factor-1α, Glucose Transporter-1 and Carbonic Anhydrase IX in rectal cancer after preoperative chemoradiotherapy.
D. – I. Vitoratou, M.Tolia, P. Liakos, N. Tsoukalas, C. Giaginis, M. Nikolaou, G. Nikolaou, G. Rigas, K. Psarianos, A. Lioupis, G. Kyrgias
JBUON I.F 1.344
8) Health related quality of life of young women with breast cancer. Review of literature
A. Yfantis, G. Intas, M. Tolia, M. Nikolaou, N. Tsoukalas, M. Lymperi, G. Kyrgias, G. Zografos, M. Kontos
JBUON I.F 1.344
9) A case of Pseudomembranous Colitis associated with Paclitaxel and Carboplatin chemotherapy for Vulvar Cancer
M. Nikolaou, K. Tsapakidis, V. Papadopoulos, C. Pontas, P. Michailidis, K. Tyrpanaki
European Journal of Gynaecological Oncology I.F 0.692
10) Weekly paclitaxel and carboplatin plus bevacizumab as first-line treatment of triple-negative breast cancer. A multicenter phase I-II trial by the Hellenic Oncology Research Group.
Saloustros E., Nikolaou M., Kalbakis K., Polyzos A., Christofillakis Ch., Kentepozidis N., Pistamaltzian N., Kourousis Ch., Vamvakas L., Georgoulias V., Mavroudis D.
Clinical Breast Cancer I.F 2.816
11) Education in oncology and career development in the web-era technology: a European survey conducted by the Hellenic Group of Young Oncologists (HeGYO)
N.G. Tsoukalas, K. Kamposioras, G. Papaxoinis, E. Aravantinou-Fatorou, A. Korogiannos, V. Papadopoulos, G. Lazaridis, M. Nikolaou, E. Voulgaris, E. Bournakis, K. Tsigaridas, M. Liontos, E. Papageorgiou, N. Chatzifoti, P. Zaxaropoulou, A. Athanasiadis, I. Varthalitis
Annals of Oncology I.F 11.855
12) Highlighting differences in education satisfaction and professional development between medical and clinical oncologists in Europe. A European survey conducted by the Hellenic Group of Young Oncologists (HeGYO)
E. Aravantinou Fatorou, G. Papaxoinis, K. Kamposioras, A. Korogiannos, V. Papadopoulos, G. Lazaridis, M. Nikolaou, E. Voulgaris, E. Bournakis, K. Tsigaridas, M. Liontos, E. Pantavou, N. Chatzifoti, P. Zaxaropoulou, I. Varthalitis, A. Athanasiadis, N.G. Tsoukalas
Annals of Oncology I.F 11.855
13) Final results of weekly paclitaxel and carboplatin plus bevacizumab as first-line treatment of triple-negative breast cancer. A multicenter phase I-II trial by the Hellenic Oncology Research Group
M. Nikolaou, E. Saloustros, A. Polyzos, C. Christophyllakis, N. Kentepozidis, L. Vamvakas, K. Kalbakis, S. Agelaki, V. Georgoulias, D. Mavroudis
Annals of Oncology I.F 11.855
14) Metastatic Soft Tissue Sarcoma: Current treatment landscape and future perspectives
E. Skafida, S. Kokkali, M. Nikolaou, A. Digklia
Expert Review of Anticancer Therapy I.F 2.212
Participations in Conventions with studies
1) “Experience and influence from a Psycho-Oncology Seminar organized by Hellenic Group of Young Oncologists”.
M. Nikolaou, E. Voulgaris, G. Lazaridis, P. Zaxaropoulou, N. Tsoukalas, V. Siafaka.
On behalf of Hellenic Group of Young Oncologists (HeGYO).
2015 World Congress of Psycho-Oncology and Psychosocial Academy Workshops in Washington. “From National to Global: Implementing the Standard of Psychosocial Care in Oncology”
Washington, DC, USA, 31 July 2015
2) “The O-Linked N-Acetyloglycosamine Containing Epitope H (OGlcNAcH) is Present in the Hypertrophic and Absent in the Resting/Reserve Chondrocytes in the Ossification Centers of Human Embryos”.
A. Zibis, M. Nikolaou, G. Nikolaou, D. Arvanitis.
XXIV International Symposium on Morphological Scienes.
Istanbul, 2-6 September 2015 Istanbul, Turkey
3) “Education and career development in oncology”: Results from a European survey conducted by the Hellenic Group of Young Oncologists.
A. Korogianno, E. Aravantinou-Fatorou, V. Papadopoulo, E. Voulgari, P. Zaxaropoulou, K. Kamposiora, G. Lazaridi, E. Mpournaki, M. Nikolaou, N. Chatzifoti, N. Tsoukala.
On behalf of Hellenic Group of Young Oncologists (HeGYO).
18th ECCO – 40th ESMO European Cancer Congress.
Vienna, Austria 27 September 2015
4) ASCO Abstract #171687 – 2016 ASCO Annual Meeting (June3-7, 2016)
Abstract Title: “Career Development and Oncology Education in Europe”: Final Results from a Survey Conducted by the Hellenic Group of Young Oncologists (HeGYO).